全文获取类型
收费全文 | 3975篇 |
免费 | 139篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 128篇 |
儿科学 | 121篇 |
妇产科学 | 148篇 |
基础医学 | 579篇 |
口腔科学 | 12篇 |
临床医学 | 227篇 |
内科学 | 947篇 |
皮肤病学 | 18篇 |
神经病学 | 510篇 |
特种医学 | 68篇 |
外科学 | 393篇 |
综合类 | 38篇 |
预防医学 | 187篇 |
眼科学 | 106篇 |
药学 | 430篇 |
中国医学 | 21篇 |
肿瘤学 | 202篇 |
出版年
2023年 | 11篇 |
2021年 | 74篇 |
2020年 | 43篇 |
2019年 | 70篇 |
2018年 | 77篇 |
2017年 | 59篇 |
2016年 | 59篇 |
2015年 | 87篇 |
2014年 | 116篇 |
2013年 | 140篇 |
2012年 | 262篇 |
2011年 | 275篇 |
2010年 | 154篇 |
2009年 | 105篇 |
2008年 | 249篇 |
2007年 | 317篇 |
2006年 | 316篇 |
2005年 | 319篇 |
2004年 | 340篇 |
2003年 | 327篇 |
2002年 | 245篇 |
2001年 | 21篇 |
2000年 | 15篇 |
1999年 | 20篇 |
1998年 | 16篇 |
1997年 | 21篇 |
1996年 | 19篇 |
1995年 | 22篇 |
1994年 | 18篇 |
1993年 | 17篇 |
1992年 | 19篇 |
1991年 | 10篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 21篇 |
1983年 | 21篇 |
1982年 | 16篇 |
1981年 | 12篇 |
1980年 | 8篇 |
1979年 | 9篇 |
1978年 | 10篇 |
1977年 | 13篇 |
1976年 | 8篇 |
1975年 | 12篇 |
1974年 | 11篇 |
1973年 | 8篇 |
1965年 | 15篇 |
1932年 | 9篇 |
排序方式: 共有4135条查询结果,搜索用时 31 毫秒
1.
Jerzy Klijanienko MD PhD Béatrix Cochand-Priollet MD PhD Wiktoria Król-Cieciorowska Michał Jeleń MD PhD Danijela Vrdoljak-Mozetič MD PhD 《Cancer cytopathology》2022,130(7):488-490
The 43rd European Congress of Cytology in Wrocław, Poland, was held as a hybrid meeting in the Fall of 2021. After nearly 2 years without in-person cytology conferences, the 43rd Congress represents 1 of the first major international scientific meetings to occur during the severe acute respiratory syndrome-coronavirus 2 pandemic. Since March 2020, the pandemic situation substantially modified the organization of scientific meetings because of both domestic and international travel restrictions, new health standards, and concern among participants, resulting in new alternative forms of virtual conferencing. Cancer (Cancer Cytopathol) 2022;130:000-000. ; 相似文献
2.
Zahra Maleki MD Zubair Baloch MD PHD Ryan Lu Khurram Shafique MD Sharon J. Song MD Kartik Viswanathan MD Rema A. Rao MD Holly Lefler CT Aisha Fatima MD Austin Wiles MD Vickie Y. Jo MD He Wang MD PhD Guido Fadda MD Celeste N. Powers MD PhD Syed Z. Ali MD Liron Pantanowitz MD Momin T. Siddiqui MD Ritu Nayar MD Jerzy Klijanienko MD PhD Guliz A. Barkan MD Jeffrey F. Krane MD PhD Esther D. Rossi MD PhD Fabiano Callegari MD Ivana Kholová MD PhD Massimo Bongiovanni MD William C. Faquin MD PhD Marc P. Pusztaszeri MD 《Cancer cytopathology》2019,127(5):306-315
3.
4.
Joe Iwanaga Vishram Singh Aiji Ohtsuka Youngil Hwang Hee‐Jin Kim Janusz Mory Kumar Satish Ravi Domenico Ribatti Paul A. Trainor Jos Ramn Saudo Nihal Apaydin Gülgün engül Kurt H. Albertine Jerzy A. Walocha Marios Loukas Fabrice Duparc Friedrich Paulsen Mariano Del Sol Philip Adds Ahmed Hegazy R. Shane Tubbs 《Clinical anatomy (New York, N.Y.)》2021,34(1):2-4
Research within the anatomical sciences often relies on human cadaveric tissues. Without the good will of these donors who allow us to use their bodies to push forward our anatomical knowledge, most human anatomical research would come to a standstill. However, many research papers omit an acknowledgement to the donor cadavers or, as no current standardized versions exist, use language that is extremely varied. To remedy this problem, 20 editors‐in‐chiefs from 17 anatomical journals joined together to put together official recommendations that can be used by authors when acknowledging the donor cadavers used in their studies. The goal of these recommendations is to standardize the writing approach by which donors are acknowledged in anatomical studies that use human cadaveric tissues. Such sections in anatomical papers will not only rightfully thank those who made the donation but might also encourage, motivate, and inspire future individuals to make such gifts for the betterment of the anatomical sciences and patient care. 相似文献
5.
Piotr Rozga Damian Kloska Sebastian Pawlak Malgorzata Teska-Kaminska Marlena Galazka Katarzyna Bukato Anna Pieczykolan Albert Jaworski Anna Molga-Kaczmarska Aleksandra Kopacz Bogna Badyra Neli Kachamakova-Trojanowska Olga Zolnierkiewicz Marta Targosz-Korecka Katarzyna Poleszak Michal Szymanik Bartlomiej Zerek Jerzy Pieczykolan Alicja Jozkowicz Anna Grochot-Przeczek 《International journal of cancer. Journal international du cancer》2020,147(4):1117-1130
Targeting of the TRAIL-DR4/5 pathway was proposed as a promising approach for specific induction of apoptosis in cancer cells. Clinical trials, however, showed inadequate efficiency of TRAIL as a monotherapy. It is a widely held view that the application of multifunctional molecules or combination therapy may lead to substantial improvement. Here, we demonstrate the effectiveness and safety of a novel chimeric protein, AD-O51.4, which is a TRAIL equipped with positively charged VEGFA-derived effector peptides. The study was performed in multiple cancer cell line- and patient-derived xenografts. A pharmacokinetic profile was established in monkeys. AD-O51.4 strongly inhibits tumor growth, even leading to complete long-term tumor remission. Neither mice nor monkeys treated with AD-O51.4 demonstrate symptoms of drug toxicity. AD-O51.4 exhibits a satisfactory half-life in plasma and accumulates preferentially in tumors. The cellular mechanism of AD-O51.4 activity involves both cytotoxic effects in tumor cells and antiangiogenic effects on the endothelium. The presence of DRs in cancer cells is crucial for AD-O51.4-driven apoptosis execution. The TRAIL component of the fusion molecule serves as an apoptosis inducer and a cellular anchor for the effector peptides in TRAIL-sensitive and TRAIL-resistant cancer cells, respectively. The FADD-dependent pathway, however, seems to be not indispensable in death signal transduction; thus, AD-O51.4 is capable of bypassing the refractoriness of TRAIL. AD-O51.4-driven cell death, which exceeds TRAIL activity, is achieved due to the N-terminally fused polypeptide, containing VEGFA-derived effector peptides. The high anticancer efficiency of AD-O51.4 combined with its safety has led to the entry of AD-O51.4 into toxicological studies. 相似文献
6.
Philip N. Patsalos Jerzy P. Szaflarski Barry Gidal Kevan VanLandingham David Critchley Gilmour Morrison 《Epilepsia》2020,61(9):1854-1868
Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox-Gastaut syndrome or Dravet syndrome in randomized, double-blind, add-on, controlled phase 3 trials. It is important to consider the possibility of drug-drug interactions (DDIs). Here, we review six trials of CBD (Epidiolex/Epidyolex; 100 mg/mL oral solution) in healthy volunteers or patients with epilepsy, which investigated potential interactions between CBD and enzymes involved in drug metabolism of common antiseizure drugs (ASDs). CBD did not affect CYP3A4 activity. Induction of CYP3A4 and CYP2C19 led to small reductions in exposure to CBD and its major metabolites. Inhibition of CYP3A4 activity did not affect CBD exposure and caused small increases in exposure to CBD metabolites. Inhibition of CYP2C19 activity led to a small increase in exposure to CBD and small decreases in exposure to CBD metabolites. One potentially clinically important DDI was identified: combination of CBD and clobazam (CLB) did not affect CBD or CLB exposure, but increased exposure to major metabolites of both compounds. Reduction of CLB dose may be considered if adverse reactions known to occur with CLB are experienced when it is coadministered with CBD. There was a small increase of exposure to stiripentol (STP) when coadministered with CBD. STP had no effect on CBD exposure but led to minor decreases in exposure to CBD metabolites. Combination of CBD and valproate (VPA) did not cause clinically important changes in the pharmacokinetics of either drug, or 2-propyl-4-pentenoic acid. Concomitant VPA caused small increases in exposure to CBD metabolites. Dose adjustments are not likely to be necessary when CBD is combined with STP or VPA. The safety results from these trials were consistent with the known safety profile of CBD. These trials indicate an overall low potential for DDIs between CBD and other ASDs, except for CLB. 相似文献
7.
Berenika Olszewska MD Anton Żawrocki MD PhD Joanna Lakomy MD PhD Joanna Karczewska PhD Jolanta Gleń PhD Monika Zabłotna PhD Marta Malek MD PhD Jerzy Jankau MD PhD Magdalena Lange MD PhD Wojciech Biernat MD PhD Roman J. Nowicki MD PhD Małgorzata Sokołowska-Wojdyło MD PhD 《International journal of dermatology》2020,59(9):1106-1112
8.
9.
10.
Antimycobacterial action of a new glycolipid‐peptide complex obtained from extracellular metabolites of Raoultella ornithinolytica 下载免费PDF全文
Marta J. Fiołka Krzysztof Grzywnowicz Ewaryst Mendyk Mirosław Zagaja Rafał Szewczyk Michał Rawski Radosław Keller Jolanta Rzymowska Jerzy Wydrych 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(12):1069-1080
In this paper, an antimycobacterial component of extracellular metabolites of a gut bacterium Raoultella ornithinolytica from D. veneta earthworms was isolated and its antimycobacterial action was tested using Mycobacterium smegmatis. After incubation with the complex obtained, formation of pores and furrows in cell walls was observed using microscopic techniques. The cells lost their shape, stuck together and formed clusters. Surface‐enhanced Raman spectroscopy analysis showed that, after incubation, the complex was attached to the cell walls of the Mycobacterium. Analyses of the component performed with Fourier transform infrared spectroscopy demonstrated high similarity to a bacteriocin nisin, but energy dispersive X‐ray spectroscopy analysis revealed differences in the elemental composition of this antimicrobial peptide. The component with antimycobacterial activity was identified using mass spectrometry techniques as a glycolipid–peptide complex. As it exhibits no cytotoxicity on normal human fibroblasts, the glycolipid–peptide complex appears to be a promising compound for investigations of its activity against pathogenic mycobacteria. 相似文献